CORT as reported
Corcept Therapeutics Incorporated reported $769M of revenue over the trailing twelve months, +12% on the year before. 11 reported series are charted on this page, each one as filed.
$769M
Revenue, trailing twelve months · to Q1 2026 · +12% against the twelve months before
- Net Income
- $47M
Net Income · −65% year on year · trailing twelve months to Q1 2026
- Free Cash Flow
- $120M
Free Cash Flow · −32% year on year · trailing twelve months to Q1 2026
- Op Margin
- −2.3%
Op Margin · trailing twelve months to Q1 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $769M | +12% | Q1 2026 |
| Net Income | $47M | −65% | Q1 2026 |
| EPS | $0.35 | −70% | Q1 2026 |
| Gross Margin | 98% | n/a | Q1 2026 |
| Op Margin | −2.3% | n/a | Q1 2026 |
| Net Margin | 5.1% | n/a | Q1 2026 |
| ROE | 15% | n/a | Q1 2026 |
| ROA | 12% | n/a | Q1 2026 |
| ROIC | 226% | n/a | Q4 2017 · 33 quarters behind |
| Free Cash Flow | $120M | −32% | Q1 2026 |
| P/E | 342 | n/a | today |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Corcept Therapeutics Incorporated (CORT) - Revenue & ProfitRevenue & ProfitCorcept Therapeutics Incorporated (CORT)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com